In a welcome move, NeoGenomics saw its Relative Strength Rating improve from 64 to 72 on Thursday.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matched up against all other stocks.
History reveals that the top-performing stocks often have an RS Rating of at least 80 as they launch their largest price moves. See if NeoGenomics can continue to show renewed price strength and clear that threshold.
Can You Really Time The Stock Market?
NeoGenomics is not currently showing a potential entry point. See if the stock goes on to form a base that could launch a new move.
The company showed 0% EPS growth in its most recent report, while sales growth came in at 10%.
NeoGenomics holds the No. 6 rank among its peers in the Medical-Services industry group. Hims & Hers Health, Castle Biosciences and NeoGenomics are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
